Lei Fang, Xinggang Wang, Ming Zhang, Petra Khan, Michael Tamm, Michael Roth
{"title":"MicroRNA-101-3p抑制COPD患者mTOR并导致线粒体断裂和细胞变性。","authors":"Lei Fang, Xinggang Wang, Ming Zhang, Petra Khan, Michael Tamm, Michael Roth","doi":"10.1155/2022/5933324","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cigarette smoke is assumed to cause the loss of airway wall structure in chronic obstructive pulmonary disease (COPD) by reducing airway smooth muscle cell (ASMC) function. It also modifies mTOR activity, microRNA (miR)-101-3p expression, and mitochondria function. Here, the link between miR-101-3p and mTOR-regulated mitochondria integrity and ASMC deterioration was assessed.</p><p><strong>Methods: </strong>Disease-specific miR-101-3p expression was determined by RT-PCR in primary ASMC (non-COPD smokers: <i>n</i> = 6; COPD: <i>n</i> = 8; healthy: <i>n</i> = 6). The regulatory effect of miR-101-3p modification on mTOR expression, mitochondrial fragmentation, and remodeling properties (<i>α</i>-SMA, fibronectin, MTCO2, and p70S6 kinase) was assessed in ASMC (healthy nonsmokers: <i>n</i> = 3; COPD: <i>n</i> = 3) by Western blotting and immunofluorescence microscopy. MiR-101-3p was modified by specific mimics or inhibitors, in ASMC stimulated with TNF-<i>α</i> (10 ng/ml) or cigarette smoke extract (CSE).</p><p><strong>Results: </strong>MiR-101-3p expression was significantly higher in ASMC of COPD patients, compared to ASMC of healthy or active smokers. MiR-101-3p expression was increased by TNF-<i>α</i> or CSE. TNF-<i>α</i> or miR-101-3p deteriorated ASMC and mitochondria, while decreasing mTOR signaling, <i>α</i>-SMA, fibronectin, and MTCO2. MiR-101-3p inhibition reduced ASMC deterioration and mitochondrial fragmentation.</p><p><strong>Conclusion: </strong>Constitutive high miR-101-3p expression characterizes COPD-ASMC, causing increased mitochondrial fragmentation and ASMC deterioration. Thus, reactivation mTOR or blocking miR-101-3p presents a potential new strategy for COPD therapy.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2022 ","pages":"5933324"},"PeriodicalIF":2.1000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744603/pdf/","citationCount":"1","resultStr":"{\"title\":\"MicroRNA-101-3p Suppresses mTOR and Causes Mitochondrial Fragmentation and Cell Degeneration in COPD.\",\"authors\":\"Lei Fang, Xinggang Wang, Ming Zhang, Petra Khan, Michael Tamm, Michael Roth\",\"doi\":\"10.1155/2022/5933324\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cigarette smoke is assumed to cause the loss of airway wall structure in chronic obstructive pulmonary disease (COPD) by reducing airway smooth muscle cell (ASMC) function. It also modifies mTOR activity, microRNA (miR)-101-3p expression, and mitochondria function. Here, the link between miR-101-3p and mTOR-regulated mitochondria integrity and ASMC deterioration was assessed.</p><p><strong>Methods: </strong>Disease-specific miR-101-3p expression was determined by RT-PCR in primary ASMC (non-COPD smokers: <i>n</i> = 6; COPD: <i>n</i> = 8; healthy: <i>n</i> = 6). The regulatory effect of miR-101-3p modification on mTOR expression, mitochondrial fragmentation, and remodeling properties (<i>α</i>-SMA, fibronectin, MTCO2, and p70S6 kinase) was assessed in ASMC (healthy nonsmokers: <i>n</i> = 3; COPD: <i>n</i> = 3) by Western blotting and immunofluorescence microscopy. MiR-101-3p was modified by specific mimics or inhibitors, in ASMC stimulated with TNF-<i>α</i> (10 ng/ml) or cigarette smoke extract (CSE).</p><p><strong>Results: </strong>MiR-101-3p expression was significantly higher in ASMC of COPD patients, compared to ASMC of healthy or active smokers. MiR-101-3p expression was increased by TNF-<i>α</i> or CSE. TNF-<i>α</i> or miR-101-3p deteriorated ASMC and mitochondria, while decreasing mTOR signaling, <i>α</i>-SMA, fibronectin, and MTCO2. MiR-101-3p inhibition reduced ASMC deterioration and mitochondrial fragmentation.</p><p><strong>Conclusion: </strong>Constitutive high miR-101-3p expression characterizes COPD-ASMC, causing increased mitochondrial fragmentation and ASMC deterioration. Thus, reactivation mTOR or blocking miR-101-3p presents a potential new strategy for COPD therapy.</p>\",\"PeriodicalId\":9416,\"journal\":{\"name\":\"Canadian respiratory journal\",\"volume\":\"2022 \",\"pages\":\"5933324\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744603/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian respiratory journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/5933324\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian respiratory journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/5933324","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 1
摘要
背景:香烟烟雾被认为通过降低气道平滑肌细胞(ASMC)功能导致慢性阻塞性肺疾病(COPD)气道壁结构的丧失。它还能改变mTOR活性、microRNA (miR)-101-3p表达和线粒体功能。本研究评估了miR-101-3p与mtor调控的线粒体完整性和ASMC恶化之间的联系。方法:通过RT-PCR检测原发性ASMC中疾病特异性miR-101-3p的表达(非copd吸烟者:n = 6;COPD: n = 8;健康:n = 6)。评估miR-101-3p修饰对ASMC患者mTOR表达、线粒体片段化和重塑特性(α-SMA、纤维连接蛋白、MTCO2和p70S6激酶)的调控作用(健康非吸烟者:n = 3;Western blotting和免疫荧光显微镜观察COPD: n = 3)。在TNF-α (10 ng/ml)或香烟烟雾提取物(CSE)刺激的ASMC中,MiR-101-3p被特异性模拟物或抑制剂修饰。结果:MiR-101-3p在COPD患者ASMC中的表达明显高于健康或活跃吸烟者的ASMC。TNF-α或CSE均升高MiR-101-3p的表达。TNF-α或miR-101-3p恶化ASMC和线粒体,同时降低mTOR信号、α-SMA、纤维连接蛋白和MTCO2。MiR-101-3p抑制可减少ASMC恶化和线粒体断裂。结论:COPD-ASMC具有组成性高表达的miR-101-3p特征,导致线粒体断裂增加和ASMC恶化。因此,重新激活mTOR或阻断miR-101-3p为COPD治疗提供了一种潜在的新策略。
MicroRNA-101-3p Suppresses mTOR and Causes Mitochondrial Fragmentation and Cell Degeneration in COPD.
Background: Cigarette smoke is assumed to cause the loss of airway wall structure in chronic obstructive pulmonary disease (COPD) by reducing airway smooth muscle cell (ASMC) function. It also modifies mTOR activity, microRNA (miR)-101-3p expression, and mitochondria function. Here, the link between miR-101-3p and mTOR-regulated mitochondria integrity and ASMC deterioration was assessed.
Methods: Disease-specific miR-101-3p expression was determined by RT-PCR in primary ASMC (non-COPD smokers: n = 6; COPD: n = 8; healthy: n = 6). The regulatory effect of miR-101-3p modification on mTOR expression, mitochondrial fragmentation, and remodeling properties (α-SMA, fibronectin, MTCO2, and p70S6 kinase) was assessed in ASMC (healthy nonsmokers: n = 3; COPD: n = 3) by Western blotting and immunofluorescence microscopy. MiR-101-3p was modified by specific mimics or inhibitors, in ASMC stimulated with TNF-α (10 ng/ml) or cigarette smoke extract (CSE).
Results: MiR-101-3p expression was significantly higher in ASMC of COPD patients, compared to ASMC of healthy or active smokers. MiR-101-3p expression was increased by TNF-α or CSE. TNF-α or miR-101-3p deteriorated ASMC and mitochondria, while decreasing mTOR signaling, α-SMA, fibronectin, and MTCO2. MiR-101-3p inhibition reduced ASMC deterioration and mitochondrial fragmentation.
Conclusion: Constitutive high miR-101-3p expression characterizes COPD-ASMC, causing increased mitochondrial fragmentation and ASMC deterioration. Thus, reactivation mTOR or blocking miR-101-3p presents a potential new strategy for COPD therapy.
期刊介绍:
Canadian Respiratory Journal is a peer-reviewed, Open Access journal that aims to provide a multidisciplinary forum for research in all areas of respiratory medicine. The journal publishes original research articles, review articles, and clinical studies related to asthma, allergy, COPD, non-invasive ventilation, therapeutic intervention, lung cancer, airway and lung infections, as well as any other respiratory diseases.